Orthotopic hepatic transplantation in the dog.
Orthotopic hepatic transplantation has become a well-established treatment modality for end-stage liver disease, and research in this field is constantly evolving. Of the 34 canine liver transplants performed in this study, 17 (50%) survived more than 3 days (mean survival time 15 days). Causes of perioperative death included hemorrhage (4), anesthetic complications (3), systemic anaphylaxis (3), portal vein thrombosis (3), hepatic venous outflow block (2), and hepatic artery thrombosis (2). Gentle handling with minimal dissection of the donor liver in situ resulted in a decreased incidence of hepatic venous outflow block. The incidence of biliary leak was similar irrespective of the method of biliary reconstruction, although the incidence of acute cholangitis was 56% in the cholecystoduodenostomy group compared with 0% in the choledochocholedochostomy cohort. Using celiac to common hepatic end-to-side arterial anastomosis with preservation of the gastroduodenal artery, thrombosis of the hepatic artery was encountered in four instances, an incidence similar to previously reported studies where end-to-end hepaticohepatic arterial anastomosis or donor aortic conduit was utilized. The incidence of postoperative intestinal intussusception was reduced from 40 to 0% in those who underwent transmesenteric intestinal plication following implantation of the liver. Among short-term survivors, sepsis was the most frequent noted complication (10), followed by intestinal intussusception (6), rejection (6), and gastrointestinal bleeding (1). Among recipient dogs that survived more than 3 days, rejection was the most common cause of graft loss (5), followed by biliary leak (4) and hepatic artery thrombosis (2).
Emre
S
S
Department of Surgery, State University of New York Health Science Center, Brooklyn 11203.
Sumrani
N
N
Youngelman
D
D
Ding
Z
Z
Davis
R
R
Hong
J H
JH
D000818:Animals; D001379:Azathioprine / Q000627:therapeutic use; D001660:Biliary Tract Diseases / Q000209:etiology; D016572:Cyclosporine / Q000627:therapeutic use; D004285:Dogs; D005260:Female; D007165:Immunosuppression Therapy / Q000379:methods; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D011183:Postoperative Complications; D011239:Prednisolone / Q000627:therapeutic use
D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine